Clinical Trial Update: A Study to Investigate Safety, Tolerability, PK and Anti-tumor Activity of TRX-221 in EGFRm NSCLC Patients [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 trial of TRX-221 in EGFR-mutant non-small cell lung cancer has been terminated; the update covers safety, tolerability, pharmacokinetics and anti-tu…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Egfr-mutant Non-small Cell Lung Cancer
• Non-small Cell Lung Cancer

Drugs mentioned

• TRX-221

Snippet

Sponsor: Therapex Co., Ltd | Conditions: Carcinoma, Non-Small-Cell Lung, EGFR Mutant Advanced Non-Small Cell Lung Cancer | Phase 1, Phase 2 | Status: TERMINATED